Abstract:Background: Genetic and experimental studies support a causal involvement of IL-6 (interleukin-6) signaling in atheroprogression. Although trials targeting IL-6 signaling are underway, any benefits must be balanced against an impaired host immune response. Dissecting the mechanisms that mediate the effects of IL-6 signaling on atherosclerosis could offer insights about novel drug targets with more specific effects. Methods: Leveraging data from 522 681 individuals, we constructed a genetic instrument of 26 variants in the gene encoding the IL-6R (IL-6 receptor) that proxied for pharmacological IL-6R inhibition. Using Mendelian randomization, we assessed its effects on 3281 plasma proteins quantified with an aptamer-based assay in the INTERVAL cohort (n=3301). Using mediation Mendelian randomization, we explored proteomic mediators of the effects of genetically proxied IL-6 signaling on coronary artery disease, large artery atherosclerotic stroke, and peripheral artery disease. For significant mediators, we tested associations of their circulating levels with incident cardiovascular events in a population-based study (n=1704) and explored the histological, transcriptomic, and cellular phenotypes correlated with their expression levels in samples from human atherosclerotic lesions. Results: We found significant effects of genetically proxied IL-6 signaling on 70 circulating proteins involved in cytokine production/regulation and immune cell recruitment/differentiation, which correlated with the proteomic effects of pharmacological IL-6R inhibition in a clinical trial. Among the 70 significant proteins, genetically proxied circulating levels of CXCL10 (C-X-C motif chemokine ligand 10) were associated with risk of coronary artery disease, large artery atherosclerotic stroke, and peripheral artery disease, with up to 67% of the effects of genetically downregulated IL-6 signaling on these end points mediated by decreases in CXCL10. Higher midlife circulating CXCL10 levels were associated with a larger number of cardiovascular events over 20 years, whereas higher CXCL10 expression in human atherosclerotic lesions correlated with a larger lipid core and a transcriptomic profile reflecting immune cell infiltration, adaptive immune system activation, and cytokine signaling. Conclusions: Integrating multiomics data, we found a proteomic signature of IL-6 signaling activation and mediators of its effects on cardiovascular disease. Our analyses suggest the interferon-γ-inducible chemokine CXCL10 to be a potentially causal mediator for atherosclerosis in 3 vascular compartments and, as such, could serve as a promising drug target for atheroprotection.

Major Adverse Cardiovascular Events: The Importance of Serum Levels and Haplotypes of the Anti-Inflammatory Cytokine Interleukin 10

Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study

Association of Polymorphisms in the IL‐10 Promoter Region with Crohn's Disease

Association Between 3 Il-10 Gene Polymorphisms and Cardiovascular Disease Risk Systematic Review with Meta-Analysis and Trial Sequential Analysis

Incidence of Augmentation in Primary Restless Legs Syndrome Patients May Not Be That High

The Prognostic Determinant of Interleukin-10 in Patients with Acute Ischemic Stroke: an Analysis from the Perspective of Disease Management

Interleukin-6 and Cardiovascular Events in Healthy Adults: MESA

Interleukin 10.G Microsatellite in the Promoter Region of the Interleukin-10 Gene in Severe Sepsis

IL-6 and hsCRP predict cardiovascular mortality in patients with heart failure with preserved ejection fraction

Association of IL-10-1082A/G Polymorphism with Cardiovascular Disease Risk: Evidence from a Case-Control Study to an Updated Meta-Analysis.

Interleukin-6 Receptor Pathways in Coronary Heart Disease: a Collaborative Meta-Analysis of 82 Studies.

Relationship of Serum Interleukin-10 and Its Genetic Variations with Ischemic Stroke in a Chinese General Population.

Clinical relevance of IL-6 gene rs1800795 polymorphism in patients with ischemic heart disease and chronic heart failure

Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome

Proteogenomic Data Integration Reveals CXCL10 as a Potentially Downstream Causal Mediator for IL-6 Signaling on Atherosclerosis

[Relationship of Genetic Variants and Cardiovascular Risk Factors with Interleukin-6 and Interleukin-10 Secreted by Monocytes].

Five-Year Changes in Inflammatory, Metabolic, and Oxidative Biomarkers and 10-Year Cardiovascular Disease Incidence: The REGICOR Cohort Study

[Interleukin 10 Gene -627 Polymorphisms in Chinese Patients with Early-Onset Coronary Heart Disease].

Soluble Interleukin-2 Receptor Combined with Interleukin-8 is a Powerful Predictor of Future Adverse Cardiovascular Events in Patients with Acute Myocardial Infarction

Exploring the therapeutic potential of interleukin-6 receptor blockade in cardiovascular disease treatment through Mendelian randomization

Elevated baseline plasma IL-8 levels are an independent predictor of long-term all-cause mortality in patients with acute coronary syndrome